Medical Herbalism and Herbal Clinical Research: A Global Perspective
Sunday J. Ameh, Obiageri O. Obodozie, Peace C. Babalola, Karnius S. Gamaniel
Journal of Pharmaceutical Research International · pp. 99–123 · Published 23 Jun 2011
10.9734/BJPR/2011/403Abstract
This review aims to sensitize researchers, regulators and other stakeholders to the centrality of clinical research to drug development from herbs used in Traditional Medicine (TM). The review uncovered and dwelt on the fact that: while clinical trials of chemical medicines (pharmaceuticals) tend to come late in the drug development chain, the reverse is often the case with herbal medicines (phytomedicines). Once the decision is made to develop a single phytochemical entity (phytopharmaceutical, example: artemisinin) from a plant, the need for such sensitization is particularly desirable, given their huge socioeconomic implications. The review emphasized that drug development from a traditional herb can: i) take the route of standardization of the herb or its extract for immediate use without further chemical manipulations; or ii) proceed along the line of isolation and other manipulations aimed at optimising bioactivity. By the first route, development proceeds directly from confirming that the pharmacological property of the herb tallies with its traditional indication, leading instantly to value addition to traditional knowledge accumulated over years. This is because herbal medicines based on time tested traditions need not undergo phased trials as would a novel pharmaceutical (or an old herb for a new indication), since their long histories often offer evidence of their safety and efficacy. In the second route, clinical studies usually come later in the chain. This is because, unlike the traditional therapeutic, the new phytopharmaceutical, taken out of its natural microenvironment and subjected to various chemical manipulations, including purification, is no longer the equivalent of the ancient remedy with predicable effects. Moreover, in this later case, interest in the new entity (an artificially concentrate isolate) may shift completely from the traditional indication of the herb, hence the need for phased trials of phytopharmaceuticals (or an old herb for a new indication), despite their natural origin.
Cited by 13
Jephtha C. Nmor · International Journal of TROPICAL DISEASE & Health · 2014
Hadi Al-Jamal, Sara Idriss, Rabih Roufayel · Viruses · 2024
Héla Fehri, Mohamed Aly Fall Seideh, Sondes Dardour · Communications in Computer and Information Science · 2016
Deepak Bhattacharya · Open Access Journal of Translational Medicine & Research · 2018
Yemisi Elizabeth Asibor, Abel Kolawole Oyebamiji, Dayo Felix Latona · Scientific Reports · 2024
Deepak Bhattacharya · Advances in Infectious Diseases · 2012
Ferda Akyuz Ozdemir, Dilek Yildirim · Seminars in Oncology Nursing · 2025
Mohamed Aly Fall Seideh, Hela Fehri, Kais Haddar · Communications in Computer and Information Science · 2016
Sunday J. Ameh, Florence D. Tarfa, Benjamin U. Ebeshi · Anemia · 2012
Amots Dafni, Saleh Aqil Khatib, Guillermo Benítez · Plants · 2021
Related research
- A Novel Catalytic Synthesis of Flavones under Autoclave Conditions and Comparative Study of Anti-cancer Activity — shares topic coverage
- HPTLC Densitogram Profile of Aqueous Distillate (Arka) from Roots of Boerhaavia diffusa — shares topic coverage
- Effects of Ethanol Extract of Unripe Annona muricata (l.) Fruits on the Haematological and Histopathological Parameters in Swiss Albino Rats Infected with Salmonella typhi — shares topic coverage
- In vitro Efficacies of Some Nigerian Medicinal Plant Extracts against Toxigenic Aspergillus flavus, A. parasiticus and A. ochraceus — shares topic coverage
- Antimalarial Efficacy of Bergenia ciliata (Saxifragaceae) Leaf Extract In vitro against Plasmodium falciparum and In vivo against Plasmodium berghei — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
13
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.